1. Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit

   • Philipp Wohlfarth
   • Thomas Staudinger
   • Arbeitsgruppe für hämato-onkologische Intensivmedizin der Österreichischen Gesellschaft für Internistische und Allgemeine Intensivmedizin und Notfallmedizin (ÖGIAIN)

   Original Paper 06 July 2014 Pages: 1629 - 1636

   

2. A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma

   • Kensuke Takaoka
   • Yasuhito Nannya
   • Mineo Kurokawa

   Original Article 08 June 2014 Pages: 1637 - 1644

   

3. Prevalence of anemia among elderly inpatients and its association with multidimensional loss of function

   • Janek Zilinski
   • Robert Zillmann
   • Gabriele Roehrig

   Original Article 29 May 2014 Pages: 1645 - 1654

   

4. Factors predicting haematopoietic recovery in patients undergoing autologous transplantation: 11-year experience from a single centre

   • Lijun Bai
   • Wei Xia
   • Matthew Greenwood

   Original Article 29 May 2014 Pages: 1655 - 1664

   

5. Eight novel F13A1 gene missense mutations in patients with mild FXIII deficiency: in silico analysis suggests changes in FXIII-A subunit structure/function

   • Arijit Biswas
   • Vytautas Ivaskevicius
   • Johannes Oldenburg

   Original Article 03 June 2014 Pages: 1665 - 1676

   

6. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol

   • Adalet Meral Güneş
   • Hale Ören
   • Gülersu İrken

   Original Article 27 May 2014 Pages: 1677 - 1684

   

7. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML)

   • Libing Wang
   • Lei Gao
   • Jianmin Wang

   Original Article 21 May 2014 Pages: 1685 - 1694

   

8. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1

   • María Rozman
   • José-Tomás Navarro
   • on behalf of Grup Català de Citologia Hematològica and Spanish CETLAM Group (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas)

   Original Article 14 May 2014 Pages: 1695 - 1703

   

9. Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry

   • Simone Oerlemans
   • Djamila E. Issa
   • Lonneke V. van de Poll-Franse

   Original Article 08 May 2014 Pages: 1705 - 1715

   

10. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study

    • Mathias Witzens-Harig
    • Robin Foá
    • Stephan Oertel

    Original Article 14 May 2014 Pages: 1717 - 1724

    

11. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)—a single region experience on consecutive patients

    • S. Eketorp Sylvan
    • J. Lundin
    • L. Hansson

    Original Article 21 May 2014 Pages: 1725 - 1733

    

12. Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients

    • Guoqi Song
    • Ling Gu
    • William C. Cho

    Original Article 25 May 2014 Pages: 1735 - 1743

    

13. ESHAP as salvage therapy for relapsed or refractory Hodgkin’s lymphoma

    • Jorge Labrador
    • Mónica Cabrero-Calvo
    • Ramón García-Sanz

    Original Article 27 May 2014 Pages: 1745 - 1753

    

14. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab

    • J. H. Park
    • D. H. Yoon
    • C. Suh

    Original Article 16 July 2014 Pages: 1755 - 1764

    

15. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment

    • Michele Dal Bo
    • Maria Ilaria Del Principe
    • Giovanni Del Poeta

    Original Article 13 June 2014 Pages: 1765 - 1774

    

16. Recombinant human interleukin-10 in patients with chronic myelomonocytic leukemia

    • Sophie Pöchlauer
    • Eva Jäger
    • Klaus Geissler

    Letter to the Editor 18 January 2014 Pages: 1775 - 1776

    

17. Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome

    • Dron Gauchan
    • Hamid Shaaban
    • Michael Maroules

    Letter to the Editor 20 February 2014 Pages: 1777 - 1778

18. Dramatic and prompt efficacy of Helicobacter pylori eradication in the treatment of severe refractory iron deficiency anemia in adults

    • Jun Yamanouchi
    • Taichi Azuma
    • Masaki Yasukawa

    Letter to the Editor 16 March 2014 Pages: 1779 - 1780

    

19. Thromboelastometry changes in myeloproliferative neoplasms—surrogate for a procoagulant haemostatic imbalance or a consequence of technical reasons?

    • Michael Nagler
    • Hugo ten Cate

    Letter to the Editor 29 March 2014 Pages: 1781 - 1782

    

20. Pneumatosis intestinalis and imatinib mesylate

    • Ciara O’Rafferty
    • Fiona McElligott
    • Owen Smith

    Letter to the Editor 20 March 2014 Pages: 1783 - 1784

    

21. The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa

    • K. T. Htun
    • J. McFadyen
    • H. A. Tran

    Letter to the Editor 02 March 2014 Pages: 1785 - 1786

    

22. Novel heterozygous c.798C>G and c.1040T>G mutations in the GBA1 gene are associated with a severe phenotype of Gaucher disease type 1

    • Maciej Machaczka
    • Monika Klimkowska

    Letter to the Editor Open access 28 February 2014 Pages: 1787 - 1789

    

23. Tandem triplication of the BCL2 gene in CD5-positive intravascular large B cell lymphoma with bone marrow involvement

    • Katsuya Yamamoto
    • Atsuo Okamura
    • Hironobu Minami

    Letter to the Editor 28 February 2014 Pages: 1791 - 1793

    

24. Paraneoplastic disseminated intravascular coagulation caused by splenic littoral cell angioma

    • Marie Caroline Schlitter
    • Heiko Rühl
    • Karin Mayer

    Letter to the Editor 29 March 2014 Pages: 1795 - 1796

    

25. Bortezomib-induced acute congestive heart failure: a case report and review of literature

    • Ashish Subedi
    • Lokesh Raj Sharma
    • Binay Kumar Shah

    Letter to the Editor 06 March 2014 Pages: 1797 - 1799

26. Independent growth of diffuse large B cell lymphoma and angioimmunoblastic T cell lymphoma originating from composite lymphoma

    • Rie Tabata
    • Chiharu Tabata
    • Masaru Kojima

    Letter to the Editor 01 February 2014 Pages: 1801 - 1803

    

27. Refractory lactic acidosis in CD30 positive gastric cancer

    • Nitipong Permpalung
    • Nischala Ammannagari
    • Sara J. Grethlein

    Letter to the Editor 19 January 2014 Pages: 1805 - 1806

    

28. Erratum to: Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study

    • Mathias Witzens-Harig
    • Robin Foá
    • Stephan Oertel

    Erratum 04 July 2014 Pages: 1807 - 1807